Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference will be held at the Westin St. Francis Hotel in San Francisco, California.

The company's management will deliver a presentation on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will engage in one-on-one meetings with investors. The presentation will be accessible via a live audio webcast on Erasca.com/events, with a replay available for 30 days following the event.

Erasca specializes in discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

News Market Reaction – ERAS

+3.00%

+3.00% Session move

In the trading session that priced this news, ERAS gained 3.00%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 43^rd Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Management will present on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will also participate in one-on-one investor meetings.

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipelines in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.

FAQ

When is Erasca (ERAS) presenting at the 2025 J.P. Morgan Healthcare Conference?

Erasca will present on Tuesday, January 14, 2025, at 9:45 am Pacific Time at the Westin St. Francis Hotel in San Francisco.

How can investors access Erasca's (ERAS) J.P. Morgan Healthcare Conference presentation?

Investors can access the live audio webcast of the presentation at Erasca.com/events. A replay will be available for 30 days after the event.

What type of cancer treatments does Erasca (ERAS) focus on developing?

Erasca focuses on developing therapies for patients with RAS/MAPK pathway-driven cancers.

Will Erasca (ERAS) management be available for individual investor meetings at the J.P. Morgan conference?

Yes, Erasca's management will participate in one-on-one investor meetings during the conference.